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Necroptosis  is a form  of regulated  necrosis  that can  be activated  by ligands  of death  receptors  and  stimuli
that  induce  the expression  of  death  receptor  ligands  under  apoptotic  deﬁcient  conditions.  Activation
of  necroptosis  by  ligands  of  death  receptors  requires  the kinase  activity  of RIP1, which  mediates  the
activation  of  RIP3  and  MLKL,  two critical  downstream  mediators  of necroptosis.  Blocking  the  kinase
activity  of RIP1,  a key druggable  target  in the necroptosis  pathway,  by  necrostatins  inhibits  the  activation
of  necroptosis  and  allows  cell  survival  and  proliferation  in  the  presence  of  death  receptor  ligands.  The
activation  of necroptosis  is  modulated  by  different  forms  of  ubiquitination,  including  K63,  linear  and
K48  ubiquitination,  as well  as  phosphorylation  of  RIP1,  RIP3  and  MLKL.  Necroptosis  is  suppressed  by
caspase-8/FADD-mediated  apoptosis.  Deﬁciency  in  caspase-8  and  FADD  leads  to  embryonic  lethality,  tis-
sue degeneration  and  inﬂammation  which  can  be suppressed  by inhibition  of RIP1  kinase  and  RIP3.  On  the
other  hand,  the  lack  of RIP3 kinase  activity  leads  to early  embryonic  lethality  which  can  be suppressed  by
the  loss  of caspase-8,  suggesting  that although  the  kinase  activity  of RIP3 is  involved  in mediating  necrop-
tosis,  the  basal  activity  of  RIP3 kinase  may  be required  for  suppressing  caspase-8  mediated  apoptosis.
Necroptosis  as well  as  RIP1-  and  RIP3-mediated  inﬂammatory  response  have  been  implicated  in mediat-
ing  multiple  human  diseases  including  TNF-mediated  hypothermia  and  systemic  inﬂammation,  ischemic
reperfusion  injury,  neurodegeneration,  Gaucher’s  disease,  progressive  atherosclerotic  lesions,  etc. Target-
ing RIP1  kinase  may  provide  therapeutic  beneﬁts  for the  treatment  of  human  diseases  characterized  by
necrosis  and  inﬂammation.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
Programmed cell death plays an important role in regulating the
ate of individual cells during development and adult life in multi-
ellular organisms. Multiple mechanisms of programmed cell death
ave been identiﬁed that function in distinct manners. Apoptosis
s a form of programmed cell death mediated by caspases [1,2].
he execution of apoptosis by caspases leads to distinguishable
orphological features, such as exposure of phosphatidylserine
PtdSer) on the outer leaﬂet of the plasma membrane, chromatin
ondensation, intranucleosomal DNA cleavage and cytoplasmic
embrane blebbing without disrupting its integrity [3,4]. The
xposure of PtdSer on apoptotic cells provides a signal for their
emoval through engulfment by macrophages and other profes-
ional phagocytic cells to lead to the clearance of dead cell bodies
ithout eliciting inﬂammatory responses [5]. Necrosis, on the other
and, is known as a form of cell death characterized by early plasma
embrane permeabilization and organelle swelling. Necrosis fre-
uently occurs when cells are challenged with excessive external
tress, such as heat, ischemia, and pathogen infection. The loss of
lasma membrane integrity during necrosis leads to the leakage
f intracellular contents, some of which – such as HMGB1 – are
nown as potent pro-inﬂammatory factors [6]. Necrosis has been
raditionally regarded as passive and unregulated and therefore,
ery little efforts had been made to investigate the mechanism of
ecrosis, despite of its prevalence in human pathology.
Interestingly, contrary to the traditional belief, recent studies
ave led to the revelation that a subset of necrosis, known as
ecroptosis, is a form of regulated cell death [7]. The activation
f necroptosis by ligands of death receptor family requires the
inase activity of RIP1 [8]. Inhibition of RIP1 kinase by necrostatins,
hich are small molecule inhibitors of RIP1 kinase, blocks the ini-
iation of necroptosis and allows cell survival. The execution of
ecroptosis involves the activation of receptor-interacting protein
 (RIP3) by RIP1 kinase [9–11] and mixed lineage kinase domain-
ike (MLKL) [12,13]. The discovery of necroptosis overturned the
raditional belief that necrosis is merely a passive process caused
y overwhelming stress, and demonstrated the feasibility of target-
ng necroptosis for the treatment of human diseases characterized
y necrotic cell death – such as ischemia-reperfusion injury and
eurodegenerative diseases. In this review, we discuss the current
nowledge regarding the necroptosis pathway and its involvement
n development and diseases.
.1. Induction of necroptosis in vitro
Necroptosis can be triggered by ligands of death receptor family
s well as by a variety of extracellular and intracellular stimuli that
nduce the expression and/or activation of ligands of death recep-
or family. Death receptors, the members of the TNFR superfamily,
re major mediators of cell death [14]. The activation of death
eceptors by their ligands recruit and activate caspase-8 through
eath domain- and death effector domain-containing adaptors and
rigger apoptosis in the absence of the NF-B survival pathway
15]. Under conditions where caspases fail to be activated, cells
ndergo necroptosis as an alternative means of cell death. TNFR1,
AS (CD95), and DR4/5 (TRAIL-R1/2) have been reported to mediate
ecroptosis in the presence of caspase inhibitor zVAD.fmk (zVAD)
7,16].
Induced expression of the ligands for death receptors can trigger
ecroptosis. For instance, certain toll-like receptor (TLR) agonists
nduce necroptosis in macrophages or microglia in an autocrine
NF-dependent manner [17]. Activation-induced cell death of T
ymphocytes is mediated by the production of FAS ligand [16]. On
he other hand, cIAP1/2 antagonist [18], TLR3 agonist [19], and
nterferon [20] may  trigger necroptosis independently of deathlopmental Biology 35 (2014) 14–23 15
receptors. The major necroptotic pathways are illustrated in Fig. 1.
It remains to be systematically characterized which cytokines,
damage-associated molecular patterns (DAMPs) and pathogen-
associated molecular patterns (PAMPs) are capable of stimulating
necroptosis and how those stress signals orchestrate necroptosis
under different pathophysiological conditions.
1.2. Molecular mechanism of necroptosis
Insights into the molecular mechanism of necroptosis were
obtained largely from studies in the context of TNFR1 engagement.
The trimerization of TNFR1 triggered by the interaction with TNF
initiates the assembly of a transient molecular complex associated
with the intracellular domain of TNFR1 named complex I, which
consists of TRADD, TRAF2, cIAP1/2 and RIP1. In complex I, RIP1
is rapidly modiﬁed by multiple forms of ubiquitination, including
linear and K63-linked polyubiquitinations, mediated by E3 ligases
LUBAC and cIAP1, respectively. Ubiquitination of RIP1 functions
as scaffolds for the recruitment of NEMO and TAK1, the critical
mediators of TNF activated the NF-B and MAP  kinase pathways,
respectively. These two  pathways keep the activation of caspase-8
in check and promote cell survival [21]. Ubiquitination of RIP1 plays
an important role in regulating its kinase activity as demonstrated
that blocking RIP1 ubiquitination by antagonizing cIAP1/2 sensi-
tizes cells to TNF-induced necroptosis [18,22,23]. TNFR2, the other
receptor of TNF that lacks death domain and does not mediate cell
death alone, facilitates TNFR1-mediated cell death by promoting
the degradation of TRAF2, a key mediator of RIP1 ubiquitination
by LUBAC and cIAP1 [24], and thus, may  sensitize TNF mediated
necroptosis by reducing the ubiquitination of RIP1.
RIP1, but not its kinase activity, functions as a scaffold in the
survival-promoting activity mediated by complex I. Inhibition of
RIP1 kinase by necrostatin-1 (Nec-1) has no effect on the activa-
tion of NF-B induced by TNF [7]. On the other hand, RIP1 kinase
activity is critical for necroptosis as shown by the ability of Nec-1 to
potently inhibit necroptosis [7,8]. Inhibition of RIP1 kinase by Nec-
1 abrogates the formation of complex IIb, also named necrosome,
which consists of RIP1, RIP3, and MLKL [10,11]. FADD and caspase-
8 can also be detected in complex IIb but caspase-8 must remain
inactive so that it does not cleave RIP1 [25]. The requirement of
RIP1 kinase for necroptosis has now been conﬁrmed by RIP1 kinase
dead knockin mutant mice. Mutant mice and cells expressing cat-
alytically inactive D138N or K45A RIP1 alleles are highly resistant
to TNF-induced necroptosis [26,27].
CYLD, a K63-speciﬁc deubiquitinating enzyme (DUB) critical for
the activation of necroptosis [28], mediates the deubiquitination
of RIP1 to facilitate the formation of complex IIb in necroptosis
[29,30]. In the absence of CYLD, the formation of complex IIb is
signiﬁcantly inhibited and RIP1 conjugated with longer polyubiqui-
tin chains accumulates in the NP-40 insoluble fraction. However, it
remains to be determined how the activation of RIP1 kinase triggers
the deubiquitination of RIP1 to lead to the formation of complex IIb.
While K63-ubiquitinated RIP1 is involved in promoting the scaf-
folding function of RIP1 in mediating NF-B activation and MAP
kinase activation, A20, a ubiquitin editing enzyme that removes
K63-linked polyubiquitin chains from RIP1 and adds K48-linked
polyubiquitin chains, targets RIP1 to degradation by proteasome
[31], negatively regulates necroptosis in L929 cells in spite of its
overall DUB activity [32]. One possible explanation is that A20
decreases the availability of unubiquitinated RIP1 in complex I [33],
which is required for complex IIb formation. Since RIP1 is subject
to multiple types of ubiquitination in a time- and likely space-
speciﬁc manner, we  have proposed that ubiquitination pattern of
RIP1 might provide an ubiquitin code that dictates the activation
of RIP1 kinase [34].
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Fig. 1. TNFR1-mediated cell death pathways of cell survival, apoptosis, and necroptosis. Association of TNFR1 with TNF trimer leads to the formation of complex I consisting
of  TRADD, TRAF2, RIP1, and cIAP1 at the cytoplasmic membrane. K63-linked polyubiquitination of RIP1 by cIAP1, leads to the recruitment of IKK complex and TAK1, activating
the  NF-B and MAPK survival pathways. In the absence of cIAP1 or cFLIP, RIP1, FADD and caspase-8 form cytosolic complex IIa to activate the caspase cascade and induce
apoptosis. Under conditions where caspase-8 activity is inhibited, RIP1 interacts with RIP3 and MLKL to form complex IIb which is involved in mediating necroptosis. The
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he  plasma membrane, where the complex mediates membrane permeabilization.
The activation of RIP1 kinase leads to the recruitment of RIP3, a
ritical downstream mediator of necroptosis. RIP1 interacts with
IP3 through the RHIM motif to form an amyloid-like signaling
omplex in necroptotic cells [35]. A critical consequence of RIP1
nteraction with RIP3 is the phosphorylation of the latter in a RIP1
inase-dependent manner [9–11]. Enforced dimerization of RIP3
an also directly lead to its autophosphorylation and activation of
LKL to lead to necrosis [36,37]. However, although the kinase
ctivity of RIP3 is important for mediating necroptosis in cell lines
timulated by TNF and mutant mice that are totally deﬁcient for
IP3 are protected from TNF induced systematic inﬂammatory
esponse syndrome (SIRS) [10,11,38,39], expression of a catalyt-
cally inactive D161N RIP3 allele in mutant mice leads to early
mbryonic lethality in a gene dose-dependent manner through the
ctivation of caspase-8-dependent apoptosis [27]. Thus, while the
igniﬁcant activation of RIP3 kinase induced by RIP1 kinase may
e critical for mediating necroptosis, the basal levels of RIP3 kinase
ctivity may  be required for suppressing apoptosis. RIP3 kinase may
erve an analogous role to that of caspase-8, but an opposite man-
er, as while the activation of caspase-8 is critical for mediating
poptosis induced by ligands of death receptors, the basal levels
f caspase-8 are also involved in suppressing necroptosis during
mbryonic development.
MLKL, also detected in complex IIb, is the most downstream
ffector of necroptosis so far identiﬁed [12,13]. The N-terminal
omain of MLKL is responsible for protein oligomerization and
ranslocation to the plasma membrane, followed by permeabil-
zation of the plasma membrane. It is under debate whethers necroptosis. RIP3 and MLKL are phosphorylated in complex IIb and translocate to
MLKL-dependent permeabilization is associated with inﬂux of
Ca2+ or Na+ ions speciﬁcally or is due to nonspeciﬁc pore forma-
tion, but Ca2+ inﬂux is functionally relevant because chelation of
Ca2+ ion confers protection against necroptosis [40–42]. The C-
terminal pseudokinase domain of MLKL interacts with RIP3 and
is phosphorylated by RIP3 in its activation loop. Structural studies
demonstrated that the activation loop is proximal to the pseudoac-
tive sites of the pseudokinase. Perturbations to the pseudoactive
sites or the activation loop circumvent the requirement for RIP3 and
leads to necrosis [43]. Activated MLKL may  translocate to intracel-
lular membrane in addition to plasma membrane, possibly leading
to permeabilization of ER, mitochondria, and lysosome [42].
2. The role of RIP1 and RIP3 in inﬂammation
Cell death and inﬂammation are inseparable in disease pathol-
ogy. Intracellular contents released by necrotic cells triggers
inﬂammatory responses while inﬂammatory factors further pro-
mote cell death, constituting a feed-forward loop. The involvement
of RIP1 kinase and RIP3 in animal models of human diseases can be
attributed to their role in necroptosis. However, evidence is emerg-
ing that RIP1 kinase activity and RIP3 might also be directly involved
in immune regulation. It was reported that RIP1 kinase promotes
zVAD-induced TNF production from L929 cells, though a transcrip-
tional mechanism regulated by EDD and Sp1 [44]. Recent studies
demonstrate similar roles of RIP1 kinase in regulating inﬂammatory
responses in primary cell types such as macrophages and dendritic
cells (DCs). It was discovered that the production of chemokine
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XCL1 (KC) by macrophages in response to TNF/zVAD treatment
as dependent on RIP1 kinase activity [26]. In DCs, deletion of
aspase-8 leads to systematic autoimmunity and hyper-response of
Cs to TLR ligands with excessive production of pro-inﬂammatory
ytokines including TNF, IL-1, IL-6, and IL-12. Remarkably, RIP1
inase activity has been shown to facilitate the production of
ytokines whereas RIP3 is not involved [45]. Therefore, it is pos-
ible that the mitigation of pathology in animal models of human
iseases upon the delivery of Nec-1 could be at least in part due to
 reduction in inﬂammation rather than promotion of cell survival.
ince RIP1 kinase serves as a key mediator of both cell death and
nﬂammation, blocking RIP1 kinase activity may  serve to inhibit
ell death and inﬂammation, which both are critically involved in
athology of human diseases.
The facilitation of inﬂammatory responses by RIP1 kinase is
igniﬁcantly activated in the absence of caspase-8 activity, sug-
esting that caspase-8 is an important suppressor of inﬂammatory
esponse. As an initiator caspase, caspase-8 can be activated in a
wo-step mechanism during apoptosis upon activation of death
eceptors by their respective ligands. Activation of caspase-8 is
ediated by induced proximity upon interaction with its adaptor
rotein FADD which leads to caspase-8 dimerization and the subse-
uent autocleavage of caspase-8 which stabilizes the active dimer
46,47]. Both steps are essential in apoptosis and occur rapidly in
eath-inducing signaling complex (DISC), which initiates a cas-
ase cascade by caspase-8-mediated cleavage and activation of
aspase-3/7, its downstream caspases, throughout the cytoplasm
nd into the nucleus. In contrast, in non-apoptotic events such as
mmune cell activation, caspase-8 cleavage is unsubstantial and
aspase-8 activity is spatially restricted. For instance, in TLR- or
FN-activated microglia, the activities of caspase-8 and caspase-3
re maintained at low levels. Cleaved caspase-3 locates primarily
lose to the lipid raft on the plasma membrane where TLR signalo-
ome assembles [48]. In antigen-stimulated T cells, caspase-8 also
xhibits limited activity [49,50]. The application of activity-based
robes revealed that active caspase-8 in T cells is restricted to lipid
aft where TCR complex is located, spatially restraining caspase-8
ctivity to speciﬁc substrates [51–53]. The non-apoptotic function
f caspase-8 is important for human health, as caspase-8 muta-
ions in human patients lead to defective lymphocyte activation
nd immunodeﬁciency [54].
RIP3 is involved in a distinct inﬂammatory pathway called
LRP3 inﬂammasome. In the absence of cIAP1/2 or XIAP, TLR4
ngagement leads to inﬂammasome formation and IL-1 pro-
uction in macrophages and DCs before cell death occurs. The
roduction of IL-1 is dependent on both caspase-1 and caspase-
, which co-exist in the NP-40 or Triton X-100 insoluble fraction
ith NLRP3 and ASC, and requires RIP3 but not RIP1 kinase activ-
ty [55,56]. Paradoxically, in a separate study with IAP-competent
ells, caspase-8 attenuates the assembly and function of NLRP3
nﬂammasome primed by TLR4 or TLR2 engagement, and the con-
equent IL-1 production is largely dependent on both RIP1 kinase
ctivity and RIP3. RIP1, RIP3, and FADD form a complex in caspase-
 deﬁcient cells following LPS treatment. It is not clear how this
omplex contributes to NLRP3 inﬂammasome, but LPS induces
LRP3 association with FADD and caspase-8, suggesting a possi-
le direct regulatory relationship between the “ripoptosome” and
LRP3 inﬂammasome [57].
In addition to the acute inﬂammatory responses described
bove, autoimmunity and chronic inﬂammation develops spon-
aneously in mice deﬁcient in Src homology region 2 (SH2)
omain-containing phosphatase-1 (SHP-1), an immune suppressor
xpressed primarily in hematopoietic cells [58]. The inﬂamma-
ory phenotype is dependent on MyD88 and microbial infection.
emarkably, deletion of Rip1 in the hematopoietic cells abro-
ates spontaneous footpad inﬂammation, and application of Nec-1lopmental Biology 35 (2014) 14–23 17
improves wound healing from microabrasion injury by attenuating
the production of inﬂammatory factors. However, genetic ablation
of Rip3 fails to protect Shp-1-deﬁcient mice, suggesting that RIP1
kinase, but not RIP3, is involved in this inﬂammation pathway [59].
3. Suppression of necroptosis is important for normal
development and tissue homeostasis
Programmed cell death during development is a mechanism
for the removal of unnecessary cells, tissues and organs. However,
although apoptosis has been proposed to be involved in the mor-
phogenesis during development, e.g. the removal of interdigital
tissue during the formation of vertebrate digits, defects in apopto-
sis execution proteins, such as caspase-3, caspase-7, apaf-1, and
Bax/Bak, do not affect embryonic development [60–62]. In con-
trast, deﬁciency of caspase-8 and its adaptor protein FADD leads
to embryonic lethality around embryonic day E10.5 [63–65]. The
discrepancy in phenotypes had been an unexplained puzzle until
the recent demonstrations that caspase-8 and FADD are required
to suppress the activation of RIP1 kinase and RIP3 during early
embryonic development. Ablation of Rip3 completely rescues the
lethality of caspase-8 deﬁcient mice [66,67], and deletion of RIP1
allows normal embryogenesis in FADD deﬁcient mice [68].
The regulation of necroptosis by caspase-8 has also been exten-
sively studied using tissue-speciﬁc knockouts. Epithelial barrier
disruption caused by ablation of FADD in intestinal epithelial cells
are completely reversed by RIP3 deﬁciency [69]. Skin inﬂammation
caused by deletion of Fadd in keratinocytes is also dependent on
RIP3 [70]. Likewise, disruption of tissue homeostasis by local induc-
tion of caspase-8 deletion in the gut and in the skin is prevented by
Rip3 ablation [71]. In the immune system, the inhibition of necrop-
tosis by FADD-caspase-8 axis maintains T cell survival during clonal
expansion. Deﬁciency of caspase-8 or overexpression of dominant
negative FADD results in failed antigen-driven clonal expansion of
T cells owing to autophagy-dependent cell death, and the cell sur-
vival and proliferation are restored by Nec-1 or genetic deletion of
Rip3 [72–74].
The protease activity of caspase-8 is required for suppressing
necroptosis [66]. Substrates of caspase-8 in the TNF downstream
pathways have been identiﬁed, such as RIP1 [25], RIP3 [75], and
CYLD [76]. RIP1, RIP3, and CYLD are important for necroptosis,
and their cleavage compromises their function. Remarkably, the
expression of a caspase-8-cleavage resistant CYLD mutant leads to
necroptosis in response to TNF in the absence of caspase inhibitor,
demonstrating the functional involvement of CYLD cleavage in the
necroptosis pathway. The activation of caspase-8 is likely mini-
mum and locally restricted in those scenarios because the cleavage
of caspase-8 to achieve maximal stability is dispensable for the
maintenance of T cell survival during clonal expansion [77,78].
Due to the speciﬁc involvement of uncleaved single-chain caspase-
8 in non-apoptotic events, it might be interesting to ﬁnd out
whether the mutation of caspase-8 self-processing site renders
cells resistant to both apoptosis and necroptosis. cFLIP, a catalyt-
ically inactive homologue of caspase-8, regulates necroptosis in
a complex manner. cFLIP is a major survival factor transcriptio-
nally induced by NF-B. The shorter splicing isoforms, cFLIPS and
cFLIPR, are inhibitors of caspase-8. As such, cFLIPS potentiates the
formation of necrosome in IAP antagonist-challenged cells [18].
The longer splicing isoform cFLIPL is a non-catalytic paralogue of
caspase-8. When expressed at physically relevant levels, cFLIPL
forms a catalytically active heterodimer with caspase-8, altering
the spectrum of substrate speciﬁcity [79,80]. Therefore, cFLIPL plays
an inhibitory role in necroptosis as caspase-8 [18]. Deletion of
cFLIP gene in mice leads to lethality around embryonic day E10.5
with similar defects as of caspase-8 and FADD deﬁcient mice. The
1  Deve
d
R
a
s
c
c
t
t
i
t
i
l
S
d
o
o
F
v
t
o
n
h
N
t
t
o
c
v
R
t
s
t
c
e
4
e
A
d
o
t
d
g
i
p
h
i
b
a
1
s
t
I
m
u
v
e
d
b
P
s
t8 W.  Zhou, J. Yuan / Seminars in Cell &
efects are rescued by double knockout of FADD and RIP3 but not
IP3 knockout alone, suggesting that cFLIP is a suppressor of both
poptosis and necroptosis [81]. cFLIP also maintains tissue homeo-
tasis, as loss of cFLIP in the intestinal epithelial cells or hepatocytes
auses cell death and perinatal lethality [82], and acute deletion of
FLIP in the skin results in local keratinocyte death and inﬂamma-
ion [71,83].cFLIP deﬁciency provides a valuable model to study the
riggers of cell death in development and tissue homeostasis. TNF
s commonly used to treat cells and organoids in the in vitro cul-
ure. TNF induces apoptosis in the absence of cFLIP or RIP1, and
nduces necroptosis in the absence of caspase-8 or FADD, recapitu-
ating all the phenotypes described in the knockout studies above.
kin damage and inﬂammation induced by acute loss of cFLIP is
ramatically rescued by neutralization of TNF but not FAS ligand
r TRAIL [71,83]. In comparison, liver damage caused by acute loss
f cFLIP in hepatocytes is rescued only by a combination of TNF,
AS ligand, and TRAIL neutralizing antibodies [82], suggesting a
ariation of cytokine distribution and receptor expression between
issues and organs. The role of TNF superfamily proteins in devel-
pment is less clear because double knockout of cFLIP and TNF has
ot been generated, but the studies on RIP1 deﬁcient mice may
elp address the question. RIP1 prevents apoptosis by activating
F-B and MAPK survival pathways. Rip1−/− cells are more sensi-
ive to TNF-induced apoptosis, and RIP1 deﬁciency in mice leads
o early postnatal lethality associated with abnormal development
f the immune system [84]. Abrogating both apoptosis-promoting
aspase-8 or FADD and necroptosis-promoting RIP3 allows sur-
ival and maturation of the mice. TNF contributes to the lethality of
ip1−/− mice as deletion of TNFR1 delays mortality. Interestingly,
ype I interferon and toll-like receptor pathways are also respon-
ible since deﬁciency of Ifnar or Trif prolongs survival of rip1−/−
nfr1−/− mice [85,86]. Therefore, TNF is one of the major culprits of
ell death under conditions where homeostasis is disrupted during
arly development and adult life under Rip1 deﬁcient condition.
. Necroptosis in animal models of human diseases
Cell death is a common feature of pathology in human dis-
ases such as ischemia-reperfusion injury and neurodegeneration.
lthough inhibition of apoptosis in many animal models of human
iseases demonstrated the beneﬁts of blocking cell death, the lack
f “druggable” targets in apoptosis pathway has so far prevented
he development of apoptosis inhibitors for the treatment of human
iseases. The discovery of necroptosis and RIP1 kinase as the “drug-
able” target in the necroptotic pathway elicited signiﬁcant interest
n studying the implication of necroptosis in human diseases. The
rotective effect of RIP1 kinase inhibition or Rip3 genetic ablation
as been identiﬁed in a number of disease models, as summarized
n Table 1. Nec-1 is the most commonly used RIP1 kinase inhibitor
ut it is known to also inhibit indoleamine-2,3-dioxygenase (IDO),
n enzyme with extensive immunomodulatory function [87]. Nec-
i, a structural analog of Nec-1 that does not inhibit RIP1 but
till targets IDO, is a better negative control than vehicle alone
o provide important support for the involvement of RIP1 kinase.
mportantly, 7-Cl-O-Nec-1, an improved analog of Nec-1 with opti-
ized potency and speciﬁcity and cannot target IDO, should be
sed in studies of animal models and in vitro (Degterev 2005)[88].
Development of molecular markers for detecting necroptosis in
ivo is critical for analyzing the role of necroptosis in human dis-
ases. Increased expression of RIP1 and RIP3 is observed in many
iseased tissues [89–91], though the elevated level of RIP1 could
e due to the inﬁltration of myeloid cells that express more RIP1.
hosphorylation of RIP1 and RIP3 are sometimes detected in tissue
amples too [92,93]. Ser166 is predicted as an autophosphoryla-
ion site of RIP1 (Degterev et al., 2008), so its phosphorylationlopmental Biology 35 (2014) 14–23
may  correlate with RIP1 kinase activity. Indeed, an antibody raised
against phospho-Ser166 detects a kinase activity-dependent signal
in TNF/zVAD-treated macrophages [26]. In view of the involvement
of RIP1 kinase in the necroptosis-independent immune pathways,
phosphorylation of MLKL may  also serve as a speciﬁc marker. A
monoclonal antibody has been developed that recognizes phospho-
Thr357/phospho-Ser358 of MLKL in necroptotic cells [42]. Such
antibodies may be used to examine tissue samples from human
pathological specimen to characterize the involvement of necrop-
tosis.
4.1. Necroptosis in TNF-induced hypothermia and systematic
inﬂammation
Systematic inﬂammatory response syndrome (SIRS) is a critical
clinical condition and sepsis, SIRS with a conﬁrmed or suspected
infection, is one of the leading causes of morbidity and mortality.
60% of microbiological diagnosis of sepsis is attributable to infection
of Gram-negative bacteria, wherein lipopolysaccharide (LPS, also
called endotoxin) plays a dominant role in eliciting inﬂammation.
TNF and IL-1 are prototypic inﬂammatory cytokines that mediate
LPS-induced shock. Though anti-TNF and anti-IL-1 antibodies failed
to prevent death in septic patients, it is likely due to the discrep-
ancy between the early production of those cytokines and the late
stage of disease when patients come to medical attention [113].
Therefore, TNF-induced acute SIRS is still a useful mouse model for
studying the mechanism of late progression of sepsis and for the
development of potential therapies. Intravenous injection of TNF
to mice leads to rapid loss of body temperature, systematic inﬂam-
mation, and mortality. Pharmacological inhibition of caspases with
zVAD exacerbates the symptoms by activating necroptosis. Genetic
deletion of Rip3 signiﬁcantly protects the mice from hypothermia
and mortality, with attenuated liver damage and late-stage inﬂam-
matory cytokine production [39]. Likewise, genetic ablation of RIP1
kinase activity mitigates hypothermia [26,27]. Interestingly, RIP1
kinase-dead knock-in renders better protection than RIP3 knock-
out, suggesting that RIP1 kinase may  play pro-inﬂammatory roles
in addition to driving necroptosis in this disease model. Small
molecule inhibitors of RIP1 kinase have also been shown to protect
mice from TNF shock, the efﬁcacy dependent on the pharmacoki-
netics of the drugs [39,114]. Those promising compounds should
next be examined in the Gram-negative bacteria infection model,
determining whether post-onset inhibition of RIP1 kinase still exert
protection.
4.2. Necroptosis in ischemia-reperfusion (I/R) injury and
traumatic injury
Ischemic injury is the most common type of cell injury in clini-
cal medicine. It is clinically divided into two stages, the reversible
stage during which the injury is amenable to repair upon restora-
tion of blood ﬂow, and the irreversible stage caused by persistent
deprivation of oxygen and metabolic substrates. In the irreversible
stage, cells die majorly through necrosis with extensive mitochon-
drial dysfunction. However, ischemia alone does not account for
all the pathology – restoration of blood ﬂow to irreversibly injured
ischemic tissues exacerbates the injury with neutrophil inﬁltration,
cytokine production, and generation of reactive oxygen species.
In vivo studies of I/R injury use animal models with complete
occlusion of one of the end-arteries to an organ. Nec-1 was ﬁrst
found to markedly reduce infarct size in a mouse model of tran-
sient focal cerebral I/R [7]. In a myocardial I/R model Nec-1 reduces
infarct size, cell damage and neutrophil inﬁltration [93]. Similar
protection was  observed in retinal and renal I/R models [94,99].
Noteworthy is that both preocclusion and postocclusion delivery
of Nec-1 exerts protective effects [7,96], suggesting that Nec-1
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Table  1
Necroptosis in animal models of human diseases.
Model of disease Induction Involvement of necroptosis References
Adult tissue homeostasis
Epithelial disruption in
the intestine
FADD deﬁciency in intestinal epithelial
cells
RIP3 expression is increased in intestinal epithelia;
Rip3 deﬁciency prevents colitis
[69]
Epidermal keratinocyte
disorder
FADD deﬁciency in epidermal
keratinocytes
Rip3 deﬁciency prevents the development of
inﬂammatory skin lesions
[70]
Defective T cell clonal
expansion and
thymopoiesis
Transgenic expression of FADD death
domain
Rip3 deﬁciency restores T cell homeostasis and
antiviral response to murine hepatitis virus
infection
[74]
Ischemia-reperfusion (I/R) injury or the like
Brain I/R injury Transient focal cerebral ischemia by left
MCA  occlusion
7-Cl-O-Nec-1 reduces the infarct size [7]
Retinal I/R injury Transient elevation of intraocular pressure
by  infusion into the anterior chamber
7-Cl-O-Nec-1 preserves the thickness and
histoarchitecture of the inner retina
[94,95]
Myocardial I/R injury Ligation of left anterior descending (LAD)
coronary artery followed by reperfusion
RIP1 and RIP3 expression and phosphorylation are
increased in I/R heart; infarct size is reduced by
Nec-1 but not Nec-1i, and long-term heart function
is  protected by Nec-1 with reduced ﬁbrosis and
inﬂammation
[93,96,97]
Myocardial ischemia Ligation of left anterior descending (LAD)
coronary artery
RIP3 expression is increased in ischemic hearts;
Rip3 deﬁciency protects heart function and reduces
T  cell inﬁltration
[98]
Renal I/R injury Transient bilateral renal pedicle clipping Renal damage is reduced by Rip3 deﬁciency and
Nec-1 but not Nec-1i
[99–101]
Kidney allograft
rejection
Kidney transplantation with total ischemic
time of 35–40 min
Rip3 deﬁciency preserves the function of kidney
allografts
[101]
Intracerebral
hemorrhage
Collagenase injection into the left striatum Nec-1 reduces the injury volume [102]
Traumatic brain injury Weight-drop in the left part of the brain Nec-1 reduces cell death in injured cortex [103]
Traumatic spinal cord
injury
Laminectomy and weight-drop at the 10th
thoracic vertebrae
Nec-1 preserves tissue viability [104]
Neurodegenerative diseases
Amyotrophic lateral
sclerosis (ALS)
Coculture of motor neurons with
astrocytes of ALS patients
Nec-1 reduces motor neuron cell death [105]
Huntington’s disease R6/2 transgenic mouse model Nec-1 delays the loss of motor function [106]
Retinitis pigmentosa Rd10 mouse model RIP1 and RIP3 expression are increased in the
degenerative retina; Rip3 deﬁciency reduces cone
cell death
[90]
Age-related macular
degeneration
Subretinal injection of poly(I:C) RIP3 expression is increased in the degenerative
retina; Rip3 deﬁciency preserves retinal
histoarchitecture and retinal pigment epithelium
survival with reduced inﬂammation
[107]
Inﬂammation
Lethal systematic
inﬂammation
Intravenous injection of TNF Rip3 deﬁciency or ablation of RIP1 kinase activity
protects mice from mortality, hypothermia and
inﬂammation
[26,27,39]
Systematic
autoimmunity
Caspase-8 deﬁciency in dendritic cells
(DCs)
Rip3 deﬁciency does not affect the systematic
autoimmunity, but Nec-1 inhibits the
hyperresponsiveness of Caspase-8 deﬁcient DCs to
TLR activation
[45]
Autoinﬂammation Shp-1 deﬁciency Wound healing from microabrasion injury is
improved by Nec-1, but not Nec-1i or Rip3
deﬁciency
[59]
ConA-induced hepatitis ConA injection Nec-1 reduces liver damage [108]
Pathogen infection
Salmonella enterica
serovar Typhimurium
infection
Infection of macrophages or mice with S.
Typhimurium
RIP1 and RIP3 are phosphorylated in the infected
macrophages; Nec-1 and Rip3 deﬁciency preserves
macrophage survival; hematopoietic Rip3
deﬁciency improves bacterial control
[92]
Cytomegalovirus
(CMV) infection
Infection of cells and mice with
M45mutRHIM CMV
Infection-induced cell death is prevented by Rip3
deﬁciency but not Nec-1; Rip3 deﬁciency restores
the infection capacity of the M45-mutant CMV
[109,110]
Human
Immunodeﬁciency
Virus Type-1 (HIV-1)
infection
Infection of CD4+ T cells with HIV-1 Nec-1 reduces necrosis and syncytia of the infected
cells but not the bystander cells
[111]
Other diseases
Atherosclerosis Ldlr deﬁciency or ApoE deﬁciency Rip3 deﬁciency reduces advanced but not early
atherosclerotic lesions
[112]
Gaucher’s disease Daily intraperitoneal injection of
conduritol B epoxide
Rip3 deﬁciency improves the lifespan and motor
coordination and reduces liver injury
[91]
Ethanol-induced liver
injury
Ethanol feeding RIP3 expression is increased in liver of ethanol-fed
mice and alcoholic liver disease patients; Rip3
deﬁciency prevents liver injury, steatosis, and
inﬂammation
[89]
Cerulein-induced acute
pancreatitis
Intraperitoneal injection of cerulein RIP3 expression is induced in pancreas; Rip3
deﬁciency attenuates pancreatic injury
[11]
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ffectively mitigates not only ischemic but reperfusion injury. The
ole of RIP3 in I/R injury is supported by the protection against
yocardial and renal I/R by ablation of RIP3 [98,100]. RIP3 pro-
ein level was found to be elevated in CA1 hippocampal neurons in
 global cerebral I/R model [115], and RIP3 phosphorylation was
bserved in myocardial I/R in a RIP1 kinase-dependent manner
93]. The involvement of necroptosis has also been demonstrated
n animal models of traumatic brain injury [103], traumatic spinal
ord injury [104], and intracerebral hemorrhage [102], which may
hare a part of the disease mechanism with I/R. In addition, kidney
ransplantation is inevitably accompanied by I/R injury, and RIP3
eﬁciency reduces injury and improves function of donor kidneys
101].
The extensive mitochondrial damage in I/R suggests a role of
itochondrial permeability transition (mPT) in the pathology, and
yclophilin D (CypD), a key mediator of mPT, is important in
ediating I/R injury [116,117]. Whether mPT  crosstalks with the
ecroptosis pathway is still elusive. CypD is required for necrosis
nduced by Ca2+ overload and reactive oxygen species [118,119],
nd Ca2+ inﬂux is one of the execution steps of necroptosis [40].
herefore, these two types of cell death may  overlap in certain
ircumstances. MEFs deﬁcient of CypD are resistant to TNF/zVAD-
nduced necroptosis (Wen Zhou and Junying Yuan, unpublished
ata). In accord with these ﬁnding, the protection of Nec-1 was
uggested to be dependent on CypD in a myocardial I/R model [96].
aradoxically, the effect of Nec-1 and RIP3 ablation is independent
f CypD in a renal I/R model [100]. The role of necroptosis in I/R
s likely inﬂuenced by the tissue environment and on the relative
ontribution of oxidative stress versus Ca2+ homeostasis.
Cell death in I/R injury is likely induced by a mixture of insults –
tarvation, oxidative stress, cytokines, DAMPs, etc. Oxygen-glucose
eprivation (OGD) is an in vitro model of ischemia resembling the
etabolic environment of ischemic cells. In hippocampal neurons
ollowing OGD challenge, protein levels of RIP1 and RIP3 increase
nd that of caspase-8 transiently declines. Cell death is inhibited
y Nec-1 or Rip3 ablation [115]. Protection against OGD by Nec-
 was also observed in retinal ganglion cells [95]. Cytokines and
AMPs, on the other hand, constitute the inﬂammatory environ-
ent of I/R. TNF and FAS ligand are critical cytokines in I/R injury,
ince neutralization of FAS ligand and TNF reduces infarct size
nd mortality in ischemic mouse brain and traumatically injured
pinal cord [120–122]. HMGB1, proposed to be a prototypic DAMP
olecule released from the nuclei of necrotic cells, can lead to the
ctivation of TLR4 to promote I/R damage [123]. Since both TNF
r FAS ligand-induced necroptosis and TLR4-mediated necroptosis
re prevented by Nec-1 [17,38], the in vitro studies are collectively
n line with the protection of necroptosis by Nec-1 against I/R injury
n vivo.
.3. Necroptosis in neurodegenerative diseases
Neurodegeneration is a condition that involves the progressive
oss of structure or function of neurons. Due to its cumulative
ature, neurodegeneration is associated with aging as well as
enetic predisposition. The exact causes for vast majority of human
eurodegenerative diseases are not clear, but neuronal cell death is
irtually the last step that could be amenable to medical interven-
ion. There is ample evidence for the implication of excitotoxicity
n neurodegeneration. Remarkably, Nec-1 protects against exci-
otoxicity in primary rat cortical culture [124] and in a mouse
ippocampal cell line [125], suggesting a mechanistic involvement
f RIP1 kinase in neurodegenerative diseases. The contribution of
ecroptosis has been demonstrated in a few in vitro models and
nimal models.
Huntington’s disease (HD) is a single-gene disorder resulting
rom autosomal dominant inheritance of expanded poly-glutaminelopmental Biology 35 (2014) 14–23
repeats in the Huntingtin (HTT) protein, the deposition of which
causes the dysfunction and death of neurons. Nec-1 reduces cell
death in an immortalized striatal neuronal line expressing mutant
HTT, and delays the onset and progression of disease in the mutant
HTT-expressing R6/2 transgenic mouse model [106]. The protection
is not as pronounced in vivo than in vitro, which calls for further
analysis of whether cell death is signiﬁcantly attenuated in R6/2
mice that express the more toxic truncated HTT, and whether pro-
tection can be observed in the full-length HTT mouse models that
resemble human pathology more closely.
Amytrophic lateral sclerosis (ALS) is a neurodegenerative con-
dition with loss of motor neurons. Though mutations of superoxide
dismutase-1 (SOD1) underlie familial ALS and a mouse model with
transgenic expression of mutant SOD1 recapitulates many of the
disease hallmarks, most ALS cases are sporadic, complicating the
mechanistic and preclinical research. It was found in a coculture
system of primary motor neurons with astrocytes from ALS patients
that both familial and sporadic ALS astrocytes compromise neu-
ronal survival in a RIP1 kinase-, MLKL-, and Bax-dependent manner
and the death of motor neurons can be rescued by Nec-1 [105].
Therefore, RIP1 inhibition could potentially beneﬁt both familial
and sporadic ALS patients. The search for the common neurotoxic
factor from ALS astrocytes is underway, which may  shed light on
the mechanistic study of ALS pathogenesis.
Retinal degeneration accounts for vision loss in the aged pop-
ulation and in patients with genetic disorders such as retinitis
pigmentosa. In the rd10 mouse model of retinitis pigmentosa, the
expression of RIP1 and RIP3 is augmented. Blockade of RIP1 kinase
or deletion of Rip3 preserves the survival and function of cone
cells which are majorly responsible for daylight vision [90]. In
dsRNA-induced retinal degeneration, a mouse model of age-related
macular degeneration, RIP1 kinase and RIP3 are also required for
cell death and inﬂammation of retinal pigment epithelium and pho-
toreceptors and the degeneration of retinal pigment epithelial cells
(Murakami et al.) [107]. Given the sensitivity of retina to necrop-
tosis, RIP kinases might be targeted for therapeutic intervention to
treat degenerative vision loss.
4.4. Necroptosis activated by pathogen invasion
Programmed cell death is often harnessed by the host to con-
trol intracellular growth of infected pathogens. Conversely, it can
be critical for viruses to maintain the survival of infected cells in
order to support its replication. Murine cytomegalovirus (MCMV)
carries several cell death suppressors, including M45-encoded viral
inhibitor of RIP activation (vIRA) which can disrupt the association
between DNA-dependent activator of interferon regulatory factors
(DAI) and RIP3 [110]. M45  mutant MCMV  induces cell death in a
RIP3-dependent, RIP1-independent manner. Because the infected
cells are rapidly killed and cleared, the immune response to this
mutant MCMV  is attenuated in wild type mice, but resumes in mice
deﬁcient in Rip3 [109].
CMV  is unique in its slow rate of replication which requires cell
death control throughout its life cycle [126]. Many other viruses
promote cell death in the lytic stage in order to release the mature
virions. Human immunodeﬁciency virus type-1 (HIV-1) kills the
infected CD4+ T cells predominantly through apoptosis, but a small
number of cells succumb to RIP1-dependent necroptosis [111]. It
has also been reported that Sendai virus triggers necroptosis in neu-
roblastoma cells, and CaMK II is an upstream factor that promotes
RIP1 phosphorylation [127].
Active replication of pathogens inevitably alarms the immune
surveillance and some bacteria have developed sophisticated
strategies to evade the immune response. Macrophage is the major
cell type that mediates innate immunity against intracellular bac-
terial infection. The induction of macrophage cell death through
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FN is a key virulence strategy used by Salmonella enterica serovar
yphimurium (S. Typhimurium).  The cell death of macrophages
nfected by S. Typhimurium in vitro requires RIP1 kinase and RIP3 but
s independent of the classical necroptosis inducer TNF. In an intra-
enous infection mouse model, genetic ablation of rip3 markedly
educes the number of dead macrophages in the spleen, lowers the
acteria burden and slightly prolongs the survival of infected mice
92]. The role of necroptosis in the oral infection model remains to
e examined, and the inhibition of necroptosis would be beneﬁ-
ial if the maintenance of cell survival is speciﬁc to macrophages
ut not intestinal epithelial cells, which support S. Typhimurium
eplication.
.5. Necroptosis in other disease models
Necroptosis has also been described in additional animal mod-
ls of human diseases. For instance, cerulein-induced pancreatitis
s ameliorated by the genetic ablation of Rip3 [11]. In addition, RIP3
as shown to be involved in progressive aortic lesions and necrosis
evelop in atherosclerotic Ldlr−/− and ApoE−/− mice [112]. Ethanol-
nduced liver injury is reduced by Rip3 deletion but not Nec-1,
hough the dose of Nec-1 used in that study may  not be sufﬁcient to
nhibit RIP1 kinase [89]. RIP3 also contributes to neuronal loss, liver
njury, and mortality induced by an irreversible glucocerebrosi-
ase inhibitor conduritol B epoxide in a mouse model of Gaucher’s
isease [91]. In addition, concanavalin A-induced hepatitis is pro-
ected by Nec-1 [108], though in vitro evidence is inadequate to
emonstrate whether Nec-1 targets necroptosis, inﬂammation, or
oth.
. Conclusions and future directions
The role of RIP1 kinase in mediating necrosis activated by ligands
f death receptors led to the acceptance of necroptosis as a form of
ecrosis that can also be regulated [7,8,16]. Tremendous progress
as since been made using genetic, cell biology, and biochemistry
pproaches, revealing the molecular mechanisms of the necropto-
is pathway. Nevertheless, many important questions remain. For
xample, we still do not understand in cells stimulated by TNF,
hat triggers the transition from complex I to complex IIb, a crit-
cal step in the activation of necroptosis. As described above, RIP1
s subject to multiple forms of phosphorylation and ubiquitination,
hich may  serve to dictate the critical downstream signaling steps,
.e. whether to promote the scaffolding function of RIP1 in regu-
ating NF-B activation and MAP  kinase activation, or to activate
ell death mechanisms to die through apoptosis or necroptosis. We
till understand very little about the patterns of RIP1 phosphory-
ation and ubiquitination under different conditions. In addition,
he role of RIP3 kinase activity in apoptosis and necroptosis is also
ery intriguing and puzzling. It is perplexing as to how the kinase
ctivity of RIP3 can be involved in mediating necroptosis as well as
uppression of apoptosis. We  speculate that RIP3 kinase may  serve a
eciprocal role in mediating necroptosis and suppressing apoptosis
s that of caspase-8 which mediates apoptosis and also suppress
ecroptosis. It may  be interesting to discover the substrate(s) of
IP3 kinase that may  be involved in suppressing apoptosis and
ediating necroptosis. Finally, the molecular mechanism by which
LKL mediates the execution of necroptosis, the most downstream
ediator of necroptosis identiﬁed so far, is still under debate.
urther studies on those questions will deepen our understand-
ng of the pathway and provide valuable tools for probing the
unction of necroptosis in human diseases. The intervention of
IP1 kinase and necroptosis may  prove to be an effective clinical
pproach to treat human diseases involving both inﬂammation and
ell death.lopmental Biology 35 (2014) 14–23 21
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